Journals / Retina-Vitreus / 2006 / Cilt: 14 - Sayı: 2

The efficacy of intravitreal triamcinolone injection in diabetic macular edema: Results of long-term follow-up

Diabetik makula ödeminde intravitreal triamsinolon enjeksiyonunun etkinliği: Uzun süreli takip sonuçları

Pages
123–126
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In order to obtain permanent therapeutic effect, reinjections are necessary.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the long-term efficacy and complications of intravitreal triamcinolone acetonide injection in diabetic macular edema.
📊
Key Findings & Data:Materials and Methods: The study included 58 eyes of 39 diabetic patients with diffuse diabetic macular edema that failed to respond previous laser photocoagulation. 4 mg/ 0.1 ml intravitreal triamcinolone acetonide injection was administered.
💡
Conclusion & Impact:In order to obtain permanent therapeutic effect, reinjections are necessary.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tomografi · optik koherens · Maküler dejenerasyon

Abstract

Purpose: To investigate the long-term efficacy and complications of intravitreal triamcinolone acetonide injection in diabetic macular edema. Materials and Methods: The study included 58 eyes of 39 diabetic patients with diffuse diabetic macular edema that failed to respond previous laser photocoagulation. 4 mg/ 0.1 ml intravitreal triamcinolone acetonide injection was administered. Best-corrected logMAR visual acuity, intraocular pressure were measured and central foveal thickness was obtained by optical coherence tomography before and at each visit after intravitreal injection. Lenticular status and complications were monitored. Differences among measurements were evaluated by FriedmanTwo-Way Analysis of Variance by Ranks. Spearman&#8217;s correlation was used for the analysis of relation between reduction of central macular thickness and visual acuity. Results: The mean follow-up period was 14,0±4,8 months (12- 26 months). The mean foveal thickness at initial examination was 709.90±295.14 &#956;m. It was 282.81±138.03 &#956;m, 323.23±199.62 &#956;m, 443.19±253.16 &#956;m, and 396.05±275.96 &#956;m at 1, 3, 6 and 12 months after intravitreal triamcinolone injection respectively. The mean central foveal thickness which was obtained at each visit postoperatively was significantly different than the baseline measurement (p<0.001). Mean bestcorrected logMAR visual acuity improved significantly from baseline at the 1st, and 3rd months (p<0.05), but there was no significant change at the 6th, and 9th months (p>0.05). During the follow-up, 22 (37.9%) eyes received reinjections of intravitreal triamcinolone. The mean period between first and second injection was 7.27±2.80 months. Fourteen (24.1%) eyes developed intraocular pressure values higher than 21 mmHg after a mean period of 2.6 months and two (3.4%) of them required filtration surgery. Six (10.3%) eyes developed cataract and four (6.9%) of them required cataract surgery. Conclusion: In diffuse diabetic macular edema, intravitreal triamcinolone injection cause significant anatomical improvement demonstrated by OCT, and functional improvement within first 3 months. The most common complications are intraocular pressure elevation and cataract development in the long-term. In order to obtain permanent therapeutic effect, reinjections are necessary.

Özet

Amaç: Diabetik makula ödeminde intravitreal triamsinolon enjeksiyonunun uzun dönem etkinliğini araştırmak ve komplikasyonlarını belirlemek. Gereç ve Yöntem: Lazer fotokoagülasyona karşın diffüz diabetik makula ödemi olan 39 olgunun 58 gözü çalışma kapsamına alındı. Bu gözlere 4 mg/0.1 ml intravitreal triamsinolon enjekte edildi. Olguların uygulama öncesinde ve sonrası takiplerinde en iyi düzeltilmiş logMAR görme keskinliği, göziçi basıncı ve Optik Koherens Tomografi (OCT) ile santral fovea kalınlığı ölçümleri alındı, lensin durumu ve takiplerde gelişebilecek komplikasyonlar kaydedildi. İstatistiksel değerlendirmelerde gruplar arası ölçümlerdeki farklılıklar için Friedman’ın iki yönlü varyans analizi ve santral fovea kalınlığında azalma ile görme keskinliği arasındaki ilişkinin değerlendirilmesi için Sperman’ın korelasyon katsayısı kullanıldı. Bulgular : Ortalama takip süresi14,0±4,8 ay (12-26ay) idi. Uygulama öncesi ortalama makula kalınlığı 709.90±295.14 μm iken 1. ayda 282.81±138.03 μm, 3. ayda 323.23±199.62 μm, 6. ayda 443.19±253.16 μm, 12. ayda ise 396.05±275.96 idi. Tüm kontrollerde elde edilen ortalama fovea kalınlıkları, uygulama öncesi kalınlıktan anlamlı olarak düşüktü (p 0.01). Takip süresinde 22 (%37.9) göze tekrarlayan enjeksiyonlar gerekti. İlk ve ikinci tedavi arasındaki süre ortalama 7.27±2.80 aydı. 14 gözde (%24.1) ortalama 2.6. ayda göziçi basıncı 21 mmHg üzerine yükseldi, bu gözlerden antiglokomatöz tedaviye cevap vermeyen 2’sine (%3.4) glokom cerrahisi uygulandı. Altı (%10.3) gözde ise katarakt gelişti, bunların 4’üne (%6.9) lens ekstraksiyonu yapıldı. Sonuç: Diabetik makula ödeminde intravitreal triamsinolon enjeksiyonu, gözlerin büyük bir kısmında OCT ile tesbit edilebilen anatomik düzelme ve erken dönemde görme artışı sağlamaktadır. En önemli komplikasyonları göziçi basınç artışı ve geç dönemde ortaya çıkan katarakt gelişimidir. Tedavinin uzun süreli etkinliğinin devam edebilmesi için tekrarlayan enjeksiyonlara gereksinim vardır.

🔖

Cite This Article

PARMAK, N., BATIOĞLU, F., ÖZMERT, E., ÇELİK, S. (2006). The efficacy of intravitreal triamcinolone injection in diabetic macular edema: Results of long-term follow-up. Retina-Vitreus, Cilt: 14 - Sayı: 2, 123–126. https://ajindex.com/articles/307943

References (16)

  1. Ferris FL, Patz A.: Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28:452-461
  2. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatmant Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806
  3. Lee CM, and Olk RJ.: Modified grid laser photocoagulation for diffuse diabetic macular edema:long-term visual results. Ophthalmology. 1991;98:1594-1602
  4. Martidis A, Duker JS, Greenberg PB, et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927
  5. Ip MS, Kumar KS.: Intravitreous triamcinolone acetonide as a treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002;120:1217-1219
  6. Antcliff RJ, Spalton DJ, Stanford MR, et al.: uveitic cystoid macular edema:An optical coherence tomography study. Ophthalmology. 2001;108:765-772
  7. Benhamou B, Massin P., Haouchine B, et al.: Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135:246-249
  8. Tano Y, Chandler D, and Machemer R.: Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816
  9. Danis RP, Bingaman DP, Yang Y, et al.: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103:2099-2104
  10. Danis RP, Ciulla TA, Pratt LM, et al.: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250
  11. Massin P, Audren F, Haouchine B, et al.: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-225
  12. Sidney S. & Castellan J.: Nonparametric Statistics for the Behavioral Sciences. NewYork,McGraw-Hill Inc.1988;7:174-183
  13. Machemer R, Sugita G, Tano Y.: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171-180
  14. Graham RO, Peyman GA.: Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92:149-154
  15. Wilson CA, Berkowitz BA, Sato Y, et al.: Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110.1155-1159
  16. Bresnick GH. Diabetic macular edema.: a review. Ophthalmology. 1986;93:989-